The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review

Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels

(2015) Elodie Gautier-Veyret et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers

(2015) Piergiorgio Cojutti et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients

(2015) Takafumi Naito et al.   CLINICA CHIMICA ACTA

The Method Quality of Cross-Over Studies Involved in Cochrane Systematic Reviews

(2015) Hong Ding et al.   PLoS One

Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring

(2012) Michael J. Dolton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers

(2012) V Michaud et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers

(2012) Thomas N. Kakuda et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers

(2011) G. Zadoyan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

(2010) M L Reitman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring

(2010) Céline Eiden et al.   XENOBIOTICA

Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers

(2009) He-Ping Lei et al.   ANNALS OF PHARMACOTHERAPY

Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine

(2009) M. Zhu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trade Herbal Products and Induction of CYP2C19 and CYP2E1 in Cultured Human Hepatocytes

(2009) Bent H. Hellum et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage

(2009) Jan-Willem C. Alffenaar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents

(2009) Roger J. M. Brüggemann et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole Pharmacokinetics and Pharmacodynamics in Children

(2009) Michael Neely et al.   CLINICAL INFECTIOUS DISEASES

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers

(2008) Bharat Damle et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Concomitant Use of Voriconazole and Rifabutin in a Patient with Multiple Infections

(2008) Joshua N Schwiesow et al.   PHARMACOTHERAPY

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetic Interaction Between Voriconazole and Efavirenz at Steady State in Healthy Male Subjects

(2007) Ping Liu et al.   JOURNAL OF CLINICAL PHARMACOLOGY